Nutraceutix Acquires CDT License for Pharmaceutical Applications

Nutraceutix Acquires CDT License for Pharmaceutical Applications

REDMOND, Wash.--Nutraceutix Inc. acquired a license for pharmaceutical applications for the first Controlled Delivery Technology (CDT™) patent from Temple University School of Pharmacy in Philadelphia. According to the company, the new license grants exclusive rights to develop, manufacture and sell prescription oral dosage forms of drugs, as well as over-the-counter (OTC) and dietary supplements, as previously licensed to Nutraceutix (www.nutraceutix.com).

"The U.S. patent for pharmaceutical applications provides Nutraceutix with a clear technological advantage over first generation controlled delivery systems," said David Howard, president and chief executive officer of Nutraceutix. More information can be obtained at Booth #1555-1557 at SupplySide West.

Share this article: Email, Slashdot, Digg, Del.icio.us, Yahoo!MyWeb, Windows Live Favorites, Furl
Add this article feed to: RSS, My Yahoo, Newsgator, Bloglines